Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Margarida BritoS EstevesR AndréM IsidoroA MoreiraPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2015)
No differences in biosimilar effectiveness were detected. The clinical relevance of the profound neutropenia found in the biosimilar cohort needs further attention.